Abstract
Impairments in cognitive function represent a consistent, non-specific, and clinically significant feature in metabolic, mood, and dementing disorders. The foregoing observation is instantiated by evidence demonstrating that these disorders share pathophysiological mechanisms including, but not limited to, aberrant insulin signaling, inflammation, and glucocorticoid activity. Moreover, these mechanisms have been consistently reported to increase vulnerability to and/or exacerbate impairments in cognitive function. Notwithstanding evidence suggesting a bidirectional relationship between disturbances in the metabolic milieu, mood, and increased risk for dementia, efficacious treatments that target cognitive impairments in these populations do not presently exist. Taken together, it is proposed that anti-diabetic agents may aid the management of mood disorders and future risk for dementia through disease modification by targeting underlying pathophysiological mechanisms (e.g., aberrant metabolic function) rather than focusing solely on symptom mitigation. The current aim is to provide a brief narrative review of extant studies that report on the potential neurotherapeutic effects of anti-diabetic agents on disturbances in mood and impairments in cognitive function.
Keywords: Depression, bipolar, diabetes, dementia, Alzheimer’s disease, insulin, insulin resistance, GLP-1, incretin, thiazolidinedione, metformin, cognition.
Current Molecular Medicine
Title:Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders
Volume: 16 Issue: 5
Author(s): D.S. Cha, M. Vahtra, J. Ahmed, P.A. Kudlow, R.B. Mansur, A.F. Carvalho and R.S. McIntyre
Affiliation:
Keywords: Depression, bipolar, diabetes, dementia, Alzheimer’s disease, insulin, insulin resistance, GLP-1, incretin, thiazolidinedione, metformin, cognition.
Abstract: Impairments in cognitive function represent a consistent, non-specific, and clinically significant feature in metabolic, mood, and dementing disorders. The foregoing observation is instantiated by evidence demonstrating that these disorders share pathophysiological mechanisms including, but not limited to, aberrant insulin signaling, inflammation, and glucocorticoid activity. Moreover, these mechanisms have been consistently reported to increase vulnerability to and/or exacerbate impairments in cognitive function. Notwithstanding evidence suggesting a bidirectional relationship between disturbances in the metabolic milieu, mood, and increased risk for dementia, efficacious treatments that target cognitive impairments in these populations do not presently exist. Taken together, it is proposed that anti-diabetic agents may aid the management of mood disorders and future risk for dementia through disease modification by targeting underlying pathophysiological mechanisms (e.g., aberrant metabolic function) rather than focusing solely on symptom mitigation. The current aim is to provide a brief narrative review of extant studies that report on the potential neurotherapeutic effects of anti-diabetic agents on disturbances in mood and impairments in cognitive function.
Export Options
About this article
Cite this article as:
Cha D.S., Vahtra M., Ahmed J., Kudlow P.A., Mansur R.B., Carvalho A.F. and McIntyre R.S., Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders, Current Molecular Medicine 2016; 16 (5) . https://dx.doi.org/10.2174/1566524016666160429121737
DOI https://dx.doi.org/10.2174/1566524016666160429121737 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Editorial (Thematic Issue: Molecular Imaging in Dementia: From the State of the Art to the New Perspectives)
Current Alzheimer Research Conformations and Biological Activities of Amyloid Beta Peptide 25-35
Current Protein & Peptide Science Poly (D,L-Lactide-co-Glycolide) Nanoparticles Loaded with Cerebrolysin Display Neuroprotective Activity in a Rat Model of Concussive Head Injury
CNS & Neurological Disorders - Drug Targets Acknowledgement List of the Reviewers
Current Alzheimer Research Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Patent Selections
Recent Patents on Cardiovascular Drug Discovery Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Current HIV Research A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Current Neurovascular Research Enzymatic Activity and Protein Interactions in Alpha/Beta Hydrolase Fold Proteins: Moonlighting Versus Promiscuity
Protein & Peptide Letters Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences Abnormal Sleep Behaviours Across the Spectrum of Alzheimer’s Disease Severity: Influence of APOE Genotypes and Lewy Bodies
Current Alzheimer Research Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry